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Hepatitis Awareness Month and 
Testing Day — May 2019
May is designated as Hepatitis Awareness Month, 
and May 19 is Hepatitis Testing Day. Hepatitis B and 
hepatitis C, the most common types of viral hepatitis in 
the United States, can cause chronic infections, and many 
persons remain unaware of their infection until serious 
complications occur. In 2016, an estimated 862,000 
and 2.4 million persons were living with hepatitis B and 
hepatitis C, respectively, despite availability of a vaccine 
and effective treatment for hepatitis B and a cure for 
hepatitis C (1,2).
Although hepatitis A is preventable through vaccina-
tion, multiple states have had outbreaks since 2016, with 
unprecedented large numbers of cases and person-to-
person spread (primarily among persons who use drugs or 
experience homelessness). A report in this issue of MMWR 
summarizes this resurgence of hepatitis A among unvac-
cinated adults at risk (3).
New cases of hepatitis C are also increasing; during 
2010–2016, they increased 3.5-fold, mostly among young 
adults (4). Recent increases in viral hepatitis infections, 
many attributed to surges in injection-drug use (4), high-
light the importance of acknowledging and combatting the 
infectious disease consequences of the nation’s opioid crisis.
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Hepatitis A virus (HAV) is primarily transmitted fecal-orally 
after close contact with an infected person (1); it is the most 
common cause of viral hepatitis worldwide, typically causing 
acute and self-limited symptoms, although rarely liver failure 
and death can occur (1). Rates of hepatitis A had declined 
by approximately 95% during 1996–2011; however, during 
2016–2018, CDC received approximately 15,000 reports of 
HAV infections from U.S. states and territories, indicating 
a recent increase in transmission (2,3). Since 2017, the vast 
majority of these reports were related to multiple outbreaks 
of infections among persons reporting drug use or homeless-
ness (4). In addition, increases of HAV infections have also 
occurred among men who have sex with men (MSM) and, 
to a much lesser degree, in association with consumption of 
imported HAV-contaminated food (5,6). Overall, reports of 
hepatitis A cases increased 294% during 2016–2018 compared 
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with 2013–2015. During 2016–2018, CDC tested 4,282 
specimens, of which 3,877 (91%) had detectable HAV RNA; 
565 (15%), 3,255 (84%), and 57 (<1%) of these specimens 
were genotype IA, IB, or IIIA, respectively. Adherence to the 
Advisory Committee on Immunization Practices (ACIP) 
recommendations to vaccinate populations at risk can help 
control the current increases and prevent future outbreaks of 
hepatitis A in the United States (7).
Hepatitis A infections among persons who meet the Council 
of State and Territorial Epidemiologists (CSTE) hepatitis A case 
definition (https://wwwn.cdc.gov/nndss/conditions/hepatitis-
a-acute/) are notified to CDC through the National Notifiable 
Diseases Surveillance System (NNDSS). Cases reported to 
CDC through NNDSS during 2013–2018 were used to 
calculate percent change (2013–2015 versus 2016–2018) by 
state and mapped using RStudio software (version 1.2.1335; 
RStudio, Inc.). Serum specimens from CSTE confirmed cases 
submitted to the CDC laboratory were tested for HAV RNA by 
polymerase chain reaction, and isolated virus was amplified to 
characterize a 315–base-pair fragment of the VP1/P2B region, 
which defines the genotype of the virus.
Overall, reports of hepatitis A cases increased 294% during 
2016–2018 compared with 2013–2015 (Figure). Eighteen 
states had lower case counts during 2016–2018 compared 
with 2013–2015. Nine states and Washington, DC had an 
increase of approximately 500%. During 2013–2018, 4,508 
HAV anti-immunoglobulin M–positive specimens under-
went additional testing at CDC. During 2013–2015, 226 
specimens underwent additional testing, of which 197 (87%) 
had detectable HAV RNA; of the RNA-positive specimens, 76 
(39%), 121 (61%), and 0 (0%) tested positive for a genotype 
IA, IB, or IIIA viral strain, respectively. In comparison, 4,282 
specimens were tested by CDC during 2016–2018, of which 
3,877 (91%) had detectable HAV RNA; 565 (15%), 3,255 
(84%), and 57 (<1%) of these specimens were genotype IA, 
IB, or IIIA, respectively.
Discussion
The number of hepatitis A infections reported to CDC 
increased during 2016–2018, along with the number of 
specimens from infected persons submitted to CDC for 
additional testing. In the past, outbreaks of hepatitis A virus 
infections occurred every 10–15 years and were associated 
with asymptomatic children (8). With the widespread adop-
tion of universal childhood vaccination recommendations 
(https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5507a1.
htm), asymptomatic children are no longer the main drivers 
of hepatitis A outbreaks (3,9). Although the overall incidence 
rate of HAV infections has decreased within all age groups, a 
large population of susceptible, unvaccinated adults who were 
not infected by being exposed to the virus during childhood 
remain vulnerable to infection by contaminated foods (typi-
cally imported from countries with endemic HAV transmis-
sion) and recently, on a much larger scale, through behaviors 
that increase risk for infection in certain vulnerable popula-
tions, such as drug use (3).
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FIGURE. Percent change in reported hepatitis A infections, by 
state — National Notifiable Diseases Surveillance System, United 
States, 2013–2015 and 2016–2018*
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Abbreviation: DC = District of Columbia.
* 2017 and 2018 case counts are provisional.
Increasingly, molecular epidemiology is employed by public 
health laboratories to better characterize hepatitis A transmis-
sion patterns. When combined with reliable epidemiologic 
data, these laboratory data can be used to identify transmission 
networks and confirm the source of exposure during common-
source outbreaks, facilitating prompt and effective public 
health response. Historically, genotype IA has been the most 
common genotype circulating in North and South America. 
During 2013–2018, HAV genotype IB predominated in the 
United States. Increasing numbers of genotype IIIA were seen, 
a genotype that is considered rare in the United States.
Decreasing new infections from hepatitis A virus can be 
achieved and sustained by maintaining a high level of popu-
lation immunity through vaccination. There is no universal 
vaccination recommendation for adults in the United States; 
however, ACIP does recommend vaccination for adults who 
plan travel to HAV-endemic countries, MSM, persons who 
use drugs, persons with chronic liver disease, and recently, 
persons experiencing homelessness (7). Continued efforts to 
increase hepatitis A vaccination coverage among the ACIP-
recommended risk groups is vital to halting the current hepa-
titis A outbreaks and reducing overall hepatitis A incidence in 
the United States.
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Summary
What is already known about this topic?
Hepatitis A is a vaccine-preventable viral infection of the liver 
that is primarily transmitted through consumption of micro-
scopic amounts of feces.
What is added by this report?
During 2016–2018, reports of hepatitis A infections in the 
United States increased by 294% compared with 2013–2015, 
related to outbreaks associated with contaminated food items, 
among men who have sex with men, and primarily, among 
persons who report drug use or homelessness.
What are the implications for public health practice?
Increasing vaccination among groups at risk for hepatitis A infection 
might halt ongoing outbreaks and prevent future outbreaks.
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